FENS 2018: CRISPR–Cas gene editing could treat Huntington’s disease

Written by Jasmine Harris, Future Science Group

Neuroscientists from Lausanne University Hospital (Lausanne, Switzerland) have found a way to disrupt the damaging effects of the mutated gene responsible for Huntington’s disease (HD). The research, presented at the 11th FENS Forum of Neuroscience (7–11 July, Berlin, Germany), highlights the therapeutic potential of the CRISPR–Cas gene editing technology to manipulate DNA in the brains of mouse models. The team utilized a viral system to deliver fluorescently tagged guide RNA into the brains of mice models of HD. This guide RNA binds the target DNA sequence and allows scientists to use the enzyme, Cas, to cut or edit DNA in...

To view the full article, please register now for access

It's completely free